Live COVID-19 Cases
  • World 244,109,329
    Confirmed: 244,109,329
    Active: 17,974,090
    Recovered: 221,175,866
    Death: 4,959,373
  • USA 46,294,210
    Confirmed: 46,294,210
    Active: 9,504,119
    Recovered: 36,033,886
    Death: 756,205
  • India 34,174,843
    Confirmed: 34,174,843
    Active: 179,592
    Recovered: 33,540,950
    Death: 454,301
  • Brazil 21,723,559
    Confirmed: 21,723,559
    Active: 222,104
    Recovered: 20,895,886
    Death: 605,569
  • UK 8,734,934
    Confirmed: 8,734,934
    Active: 1,479,294
    Recovered: 7,116,179
    Death: 139,461
  • Russia 8,205,983
    Confirmed: 8,205,983
    Active: 833,318
    Recovered: 7,143,137
    Death: 229,528
  • France 7,120,863
    Confirmed: 7,120,863
    Active: 93,804
    Recovered: 6,909,596
    Death: 117,463
  • Spain 4,997,732
    Confirmed: 4,997,732
    Active: 62,168
    Recovered: 4,848,432
    Death: 87,132
  • Italy 4,737,462
    Confirmed: 4,737,462
    Active: 74,016
    Recovered: 4,531,644
    Death: 131,802
  • Germany 4,464,667
    Confirmed: 4,464,667
    Active: 168,873
    Recovered: 4,200,000
    Death: 95,794
  • China 96,758
    Confirmed: 96,758
    Active: 564
    Recovered: 91,558
    Death: 4,636
Generic selectors
Exact matches only
Search in title
Search in content
Generic selectors
Exact matches only
Search in title
Search in content
covid free office

BY James Hingley


Booster Vaccine Against Unknown Covid Variants

The world’s first variant-proof booster vaccine is being trialled.

SEPTEMBER 22  2021


A trial in Manchester is underway, exploring the possibility of a vaccine that protects against unknown variants of Covid-19.

The US pharmaceutical company Gritstone has launched the phase one trial in collaboration with the University of Manchester and Manchester University NHS Foundation Trust. The drug is a self-amplifying mRNA second-generation Sars-CoV-2 vaccine (SAM). The president of Gritstone, Dr Andrew Allen, explained the thinking behind the vaccine:

‘Our hypothesis is that a different vaccine such as GRT-R910 might complement the primary immune response from pre-existing vaccination with a first generation Covid vaccine in such a way that it would provide more benefit than an additional dose of the same vaccine.’

There are currently 20 participants in the trial. All are aged 60 or over and have received the Oxford/AstraZeneca vaccine. Each participant will receive the booster, one of two different doses.

A couple from Bolton, Andrew and Helen Clarke, was the first to receive the booster jab. Both were eager to participate in the trial. Mrs Clarke is a retired NHS nurse and had been involved in research previously. Mr Clarke said, because they are both retired and had had a comparatively easy lockdown, they felt this was a small part they could play in helping the world return to normal.


How does it work?

The current Covid-19 vaccines work by targeting a particular spike protein of the virus. The presence of a spike protein allows the virus to penetrate host cells and therefore cause the infection.

However, as different strains of the virus have appeared, such as the highly contagious Delta variant, the vaccines have become less effective.

Unlike the present incarnations of the vaccines, the SAM vaccine, named GRT-R910, contains viral proteins that are less likely to evolve. As a result, the vaccine has the potential to provoke a stronger memory T-cell response over time.

The SAM vaccine introduces special immune cells (CD8+ T cells). These form part of the body’s immune response to viruses. The hope from the trials is that the vaccine will exhibit a strong and durable immune response. If this happens, the SAM vaccine could reduce the number of vaccine doses needed. It could even eliminate the need for repeat administrations.

The chief investigator of the study and a consultant in infectious diseases and tropical medicine at North Manchester General hospital, Andrew Ustianowski, said the following about the trial:

‘We think GRT-R910 as a booster vaccination will elicit strong, durable, and broad immune responses, which are likely to be critical in maintaining protection of this vulnerable elderly population who are particularly at risk of hospitalisation and death.’

Ustianowski also went into greater detail on how the vaccine works:

‘This vaccine targets not just the spike protein but also the nucleocapsid protein. This varies much less than the spike protein and therefore the hope is that it will be more proof against current and future variants.’

Whilst examining how effective the SAM vaccine is, the trial will also evaluate the vaccine’s safety and tolerability. The first phase will only feature over-60s. Future studies will examine the efficacy of the vaccine among more vulnerable groups.

Professor Ian Bruce, who is the Chair of the Manchester COVID-19 Research Rapid Response Group (RRRG), expressed his hopes for the SAM vaccine:

‘If successful, we feel it has the potential to have play a significant role in the battle against COVID-19, which has so devastated vulnerable populations across the globe.’

There is clear excitement around Gritstone’s trial. The effectiveness of the vaccines against new variants is a major concern. The idea that there is a vaccine in the works that could protect against variants is welcome. If the vaccine proves effective, the need to tweak the vaccines to tackle new variants would be removed.

The results from the trial are expected by next Spring.



About the Author: James Hingley

James Hingley is a contributing Features Writer with extensive expertise in International Relations, Politics and Culture.

Recommended for you

What is COP26 and Why Does it Matter?

The COP26 climate summit is on the horizon, but what exactly will it entail? Who is attending? And perhaps more importantly, who isn’t?